ArticleBlood advances2020
KIR B donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplantation.
Article in Blood advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Effects of donor killer-cell immunoglobulin-like receptor genotypes on clinical outcome after allogeneic hematopoietic stem cell transplantation-a systematic review and meta-analysis.Frontiers in immunology · 2026Pooled it
- Effect of NK cell receptor genetic variation on allogeneic stem cell transplantation outcome and in vitro NK cell cytotoxicity.Scientific reports · 2024Article
- Phase I study of safety and efficacy of allogeneic natural killer cell therapy in relapsed/refractory neuroblastomas post autologous hematopoietic stem cell transplantation.Scientific reports · 2024Article
- Donor KIR2DL1 Allelic Polymorphism Influences Posthematopoietic Progenitor Cell Transplantation Outcomes in the T Cell Depleted and Reduced Intensity Conditioning Setting.Transplantation and cellular therapy · 2024Article
- Increased donor inhibitory KIR are associated with reduced GVHD and improved survival following HLA-matched unrelated donor HCT in paediatric acute leukaemia.British journal of haematology · 2024Article
- Systematic evaluation of donor-KIR/recipient-HLA interactions in HLA-matched hematopoietic cell transplantation for AML.Blood advances · 2024Article
- Human NK cells and cancer.Oncoimmunology · 2024Review
- DonorFrontiers in immunology · 2024Article
- The role and novel use of natural killer cells in graft-versus-leukemia reactions after allogeneic transplantation.Frontiers in immunology · 2024Review
- Targeting KIR as a novel approach to improve CAR-NK cell function.Journal of translational genetics and genomics · 2023Article
- Crosstalk of Mast Cells and Natural Killer Cells with Neurons in Chemotherapy-Induced Peripheral Neuropathy.International journal of molecular sciences · 2023Review
- Large case-control study indicates no association of KIR genotype and risk of developing acute myeloid leukemia.Blood advances · 2023Article
- Prospects and Advances in Adoptive Natural Killer Cell Therapy for Unmet Therapeutic Needs in Pediatric Bone Sarcomas.International journal of molecular sciences · 2023Review
- Human natural killer cells: Form, function, and development.The Journal of allergy and clinical immunology · 2023Review
- NK cell defects: implication in acute myeloid leukemia.Frontiers in immunology · 2023Review
- KIR2DS2 Expression Identifies NK Cells With Enhanced Anticancer Activity.Journal of immunology (Baltimore, Md. : 1950) · 2022Article
- Practical Considerations and Workflow in Utilizing KIR Genotyping in Transplantation Medicine.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Increased donor inhibitory KIR with known HLA interactions provide protection from relapse following HLA matched unrelated donor HCT for AML.Bone marrow transplantation · 2021Article
- Relevance of Polymorphic KIR and HLA Class I Genes in NK-Cell-Based Immunotherapies for Adult Leukemic Patients.Cancers · 2021Review
- Review
Corrections and comments
- Erratum issued
Authors and funding
24 authors at 13 institutions in 2 countries.
Funding
Abstract
Natural killer (NK) cell recognition and killing of target cells are enhanced when inhibitory killer immunoglobulin-like receptors (KIR) are unable to engage their cognate HLA class I ligands. The genes of the KIR locus are organized into either KIR B haplotypes, containing 1 or more activating KIR genes or KIR A haplotypes, which lack those genes. Analysis of unrelated donor (URD) hematopoietic cell transplants (HCT), given to acute myeloid leukemia (AML) patients between 1988 and 2009, showed that KIR B haplotype donors were associated with better outcomes, primarily from relapse protection. Most of these transplants involved marrow grafts, fully myeloablative (MAC) preparative regimens, and significant HLA mismatch. Because the practice of HCT continues to evolve, with increasing use of reduced intensity conditioning (RIC), peripheral blood stem cell grafts, and better HLA match, we evaluated the impact of URD KIR genotype on HCT outcome for AML in the modern era (2010-2016). This analysis combined data from a prospective trial testing URD selection based on KIR genotypes (n = 243) with that from a larger contemporaneous cohort of transplants (n = 2419). We found that KIR B haplotype donors conferred a significantly reduced risk of leukemia relapse and improved disease-free survival after RIC, but not MAC HCT. All genes defining KIR B haplotypes were associated with relapse protection, which was significant only in transplant recipients expressing the C1 epitope of HLA-C. In the context of current HCT practice using RIC, selection of KIR B donors could reduce relapse and improve overall outcome for AML patients receiving an allogeneic HCT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.